Prophylactic HPV vaccines;Vacinas profiláticas para o HPV

Revista Brasileira de Ginecologia e Obstetricia

Volumn 29, Issue 6, 2007, Pages 281-284

  Derchain, Sophe Françoise Mauricette ^a,b   Sarian, Luis Otávio Zanatta ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b Cidade Universitaria   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 37349037558     PISSN: 01007203     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0100-72032007000600001     Document Type: Editorial

References (17)

1. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24 Suppl 3:S1-S10.
2. Lazcano-Ponce E, Alonso P, Ruiz-Moreno JA, Hernandez-Avila M. Recommendations for cervical cancer screening programs in developing countries. The need for equity and technological development. Salud Publica Mex. 2003;45 Suppl 3:S449-62.
3. Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest. 2006;116(5):1167-73.
4. Tewari KS, DiSaia PJ. Primary prevention of uterine cervix cancer: focus on vaccine history and current strategy. Obstet Gynecol Clin North Am. 2002;29(4):843-68.
5. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271-8.
6. Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine. 2006;24(27-28):5571-83.
7. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst. 2001;93(4):284-92.
8. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347(21):1645-51.
9. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364(9447):1757-65.
10. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367(9518):1247-55.
11. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007;369(9574):1693-702.
12. Ault KA; Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007;369(9576):1861-8.
13. Schiller JT, Nardelli-Haefliger D. Chapter 17: second generation HPV vaccines to prevent cervical cancer. Vaccine. 2006;24 Suppl 3:S147-53.
14. Franco EL, Cuzick J, Hildesheim A, de Sanjose S. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine. 2006;24 Suppl 3:S171-7.
15. Zimmerman RK. Ethical analysis of HPV vaccine policy options. Vaccine. 2006;24(22):4812-20.
16. Goldie SJ, Kim JJ, Myers E. Chapter 19: cost-effectiveness of cervical cancer screening. Vaccine. 2006;24 Suppl 3:S164-70.
17. Goldie SJ, Grima D, Kohli M, Wright TC, Weinstein M, Franco E. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer. 2003;106(6):896-904.